Trial abstract · §3
SYNERGY-NASH — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis at week 52 | Resolution in 44 % to 62 % across doses versus 10 % with placebo | Low |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Tirzepatide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 29.0 | 9.5 | SURMOUNT-1 (15 mg, 72 weeks) |
| Diarrhoea | 23.4 | 7.3 | SURMOUNT-1 |
| Constipation | 11.7 | 5.8 | SURMOUNT-1 |
| Vomiting | 12.8 | 2.6 | SURMOUNT-1 |
| Dyspepsia | 9.1 | 2.9 | SURMOUNT-1 |
| Injection-site reaction | 5.6 | 0.9 | SURMOUNT-1 |
| Alopecia | 5.4 | 1.0 | SURMOUNT-1 |
| Cholelithiasis | 1.6 | 0.4 | SURMOUNT-1 |
Compound Evidence Institute · CEI-TR-0061/3 · https://compoundevidence.com/trials/synergy-nash/results/ · retrieved 30 July 2026